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The treatment of hepatitis C virus infection (HCV) by a
combination of pegylated interferon and ribavirin,
according to early viral kinetics, leads to a sustained vir-
ological response (SVR) in more than 50% of patients
with chronic infection. This SVR is a complete recovery
of the infection but more than 50% of genotype 1-
infected patients do not achieve SVR.
A better understanding of the viral cycle, and the
characterization of viral enzymes which are potential
targets, resulted in the development of new molecules,
direct acting antiviral drugs (DAA) targeted against
HCV, either specific of genotype 1 (NS3/NS4A protease
inhibitors and NS5B polymerase inhibitors) or with a
wider spectrum (NS5A or entry inhibitors), and non-
specific antivirals (new interferons, cyclophilin inhibi-
tors). The results of these phase II and III trials which
clearly demonstrated a 20 to 30% increase in the SVR
rate of genotype 1-infected patients, either naive or
treatment experienced.
These new drugs has now been approved by the end
of 2011, after a temporary approval for compassionate
use in cirrhotic genotype 1 patients with previous
relapse or partial response to the combination therapy
and a new turn appears with the “interferon free regi-
mens” which combine different direct acting antivirals.
The complete virologic recovery which is achieved with
all the antiviral treatments clearly reduces the rates of
liver-related morbidity and mortality but, in the absence
of biopsy-proven cirrhosis reversal, the risk of occur-
rence of hepatocellular carcinoma is still present and
requires a regular US follow-up in those patients with
extensive fibrosis or cirrhosis for an early screening. In
the experienced patients with active replication, new
antivirals are mandatory to reduce the risks of complica-
tions, including liver transplantation, which is high,
especially in patients with rapid fibrosis.
In the future, the main limitations of triple therapy
will be safety (cutaneous rash or anemia which may be
controlled), cost, compliance, viral resistance, and drug-
drug interactions that must be avoided by educating
patients and physicians.
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